Phase II Anti-α2ap Antibody Trial for DVT Patients Launched by Bayer

Bayer has initiated a Phase II clinical trial for an innovative antibody, BAY3018250, which is designed to target alpha2 antiplasmin (α2ap) in patients suffering from deep vein thrombosis (DVT). The study, known as SIRIUS, aims to evaluate the efficacy and safety of this first-in-class anti-α2ap antibody. The primary function of α2ap is to regulate the activity of plasmin, an enzyme that plays a critical role in the balance between clot formation and dissolution.

The trial follows a successful initial human trial and is structured as a randomized, double-blind, placebo-controlled, multi-center study. It is anticipated that the results will shed light on the potential of the antibody as a thrombolytic agent, offering new avenues for treating conditions of significant medical importance.

Christian Rommel, a key executive at Bayer AG's Pharmaceuticals Division, expressed enthusiasm for the progression of the anti-α2ap antibody into this new phase of clinical development. He highlighted the importance of this research in providing a more precise method to modulate plasmin and break down blood clots, which could be a game-changer in the treatment of DVT.

Bayer's commitment to cardiovascular diseases is evident through its leadership in cardiology and its ongoing development of innovative treatments for high-unmet medical needs. The company's strategy focuses on transforming its portfolio into precision cardiology, addressing the substantial burden of cardiovascular diseases and fostering long-term growth. The current portfolio encompasses a range of innovative products and compounds at various stages of development.

As a global enterprise, Bayer has a strong presence in the life science sectors of health care and nutrition. The company's mission is to support global and aging populations in overcoming major challenges and to drive sustainable development. With a commitment to innovation and growth, Bayer seeks to increase its earning power and create value. The company's brand is synonymous with trust, reliability, and quality worldwide. In the fiscal year 2022, Bayer employed approximately 101,000 people and achieved sales of 50.7 billion euros, with R&D expenses amounting to 6.2 billion euros before special items.